Dr. Quincy Chu
Claim this profileCross Cancer Institute
Studies Cancer
Studies Tumors
17 reported clinical trials
48 drugs studied
Area of expertise
1Cancer
Stage IV
Stage III
ROS1 positive
2Tumors
Stage IV
Stage III
CYP2D6 positive
Affiliated Hospitals
Clinical Trials Quincy Chu is currently running
OC-001
for Advanced Cancers
This trial is testing a new treatment called OC-001, both by itself and with other drugs that help the immune system fight cancer. It aims to help patients with various types of cancer by making their immune system better at attacking cancer cells.
Recruiting1 award Phase 1 & 214 criteria
GSK4524101 + Niraparib
for Cancer
This trial is testing a new drug called GSK4524101 alone and with another drug called niraparib. It aims to find the highest safe dose and understand its effects, likely targeting cancer patients who need new treatment options. Niraparib is a drug taken by mouth that is used to maintain treatment in ovarian cancer.
Recruiting1 award Phase 1 & 24 criteria
More about Quincy Chu
Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Quincy Chu has experience with
- Dostarlimab
- Niraparib
- Repotrectinib (TPX-0005)
- BI 754091
- BI 836880
- BI 754111
Breakdown of trials Quincy Chu has run
Cancer
Tumors
Solid Tumors
Non-Small Cell Lung Cancer
Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Quincy Chu specialize in?
Is Quincy Chu currently recruiting for clinical trials?
Are there any treatments that Quincy Chu has studied deeply?
What is the best way to schedule an appointment with Quincy Chu?
What is the office address of Quincy Chu?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.